Tubin Slavisa, Khan Mohammad K, Gupta Seema, Jeremic Branislav
MedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700 Wiener Neustadt, Austria.
Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, Atlanta, GA 30322, USA.
Cancers (Basel). 2021 Feb 12;13(4):775. doi: 10.3390/cancers13040775.
The overall prognosis and survival of non-small cell lung cancer (NSCLC) patients remain poor. The immune system plays an integral role in driving tumor control, tumor progression, and overall survival of NSCLC patients. While the tumor cells possess many ways to escape the immune system, conventional radiotherapy (RT) approaches, which are directly cytotoxic to tumors, can further add additional immune suppression to the tumor microenvironment by destroying many of the lymphocytes that circulate within the irradiated tumor environment. Thus, the current immunogenic balance, determined by the tumor- and radiation-inhibitory effects is significantly shifted towards immunosuppression, leading to poor clinical outcomes. However, newer emerging evidence suggests that tumor immunosuppression is an "elastic process" that can be manipulated and converted back into an immunostimulant environment that can actually improve patient outcome. In this review we will discuss the natural immunosuppressive effects of NSCLC cells and conventional RT approaches, and then shift the focus on immunomodulation through novel, emerging immuno- and RT approaches that promise to generate immunostimulatory effects to enhance tumor control and patient outcome. We further describe some of the mechanisms by which these newer approaches are thought to be working and set the stage for future trials and additional preclinical work.
非小细胞肺癌(NSCLC)患者的总体预后和生存率仍然很差。免疫系统在驱动肿瘤控制、肿瘤进展以及NSCLC患者的总体生存方面起着不可或缺的作用。虽然肿瘤细胞有多种逃避免疫系统的方式,但对肿瘤具有直接细胞毒性的传统放疗(RT)方法,会通过破坏照射肿瘤环境中循环的许多淋巴细胞,进一步给肿瘤微环境增加额外的免疫抑制。因此,由肿瘤和辐射抑制作用决定的当前免疫原性平衡显著向免疫抑制方向转变,导致临床结果不佳。然而,新出现的证据表明,肿瘤免疫抑制是一个“弹性过程”,可以被操纵并转化回能够实际改善患者预后的免疫刺激环境。在这篇综述中,我们将讨论NSCLC细胞和传统RT方法的天然免疫抑制作用,然后将重点转向通过新型的、正在出现的免疫和RT方法进行免疫调节,这些方法有望产生免疫刺激作用以增强肿瘤控制和患者预后。我们还将进一步描述这些新方法被认为起作用的一些机制,并为未来的试验和更多临床前工作奠定基础。